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IL-6  Interleukin 6 
IL-10  Interleukin 10 
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TNF-α Tumor Necrosis Factor-alpha 
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Abstract 
BACKGROUND: Arthritis and other rheumatic conditions are a growing health 
problem, in terms of prevalence, disability and cost. Rheumatism is classified as 
chronic, systemic, and autoimmune diseases. Major symptoms are synovial 
inflammation and swollen joints, autoantibody production, deformation of cartilage 
and bone structures, and systematic features such as cardiovascular, pulmonary, 
psychological and skeletal disorders. The mortality rate in patients with rheumatoid 
arthritis (RA) is 1.5 – 1.6 compared to that of the general public, and cardiovascular 
diseases (CVD) account for 40-50% of the deaths. In addition, a five-fold increased 
CVD-risk, was observed in female patients with RA who were diagnosed at a young 
age. Scientific studies have shown that aerobic interval training of high intensity is 
effective in improving general physical status and cardiovascular health, but is not yet 
used as a treatment option for people with rheumatism. The aim of the present study 
was to find out if ten weeks of high intensity interval training was well tolerated by 
people with rheumatic diseases, and if it would improve activity of the disease, quality 
of life, and traditionally risk factors for cardiovascular diseases.  
 
METHODS: Eighteen women with RA and juvenile idiopathic arthritis (JIA), aged 20-
50 years, were recruited to this cross-over study. Participants performed supervised 
interval training 2 times a week for 10 weeks on a spinning bike. The exercises 
consisted of four 4-minute intervals at ~90% of maximal heart rate (HRmax), 
interspersed with 3 minute recovery periods at ~70% of HRmax. Maximal oxygen 
uptake (VO2max), HRmax, one minute heart rate recovery (1-minHRR), blood pressure, 
body composition, blood analysis, molecular status (TNF-α, Interleukin-6 (IL-6), 
Human Cartilage Oligometric Matrix Protein (COMP) and Pentraxin-3), disease 
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activity status, and questionnaires (Visual analogue scales (VAS), Modified Stanford 
Health Assessment Questionnaire (MHAQ), and SF-35) were measured before and 
after both exercise and control periods. Statistical analyses were performed using the 
software program SPSS.  
 
RESULTS: As a consequence of high intensity interval training (HIIT), the results 
showed that; VO2max increased by 12.2% (p < 0.001), 1-minHRR decreased by 3.7% 
(p = 0.02), BMI, body fat, visceral fat and waist circumference decreased by 1.2% (p= 
0.04), 1.0% (p= 0.05), 0.2% (p= 0.08) and 1.6% (p=0.004), respectively, whereas 
muscle percentage increased by 0.6% (p=0.03). Significant differences were found 
for serum glucose (increased 6.3%, p=0.05), haemoglobin (decreased 2.2%, p= 0.03) 
and ferritin (decreased 24.0%, p= 0.006). High sensitive CRP (hsCRP) level 
decreased by 41.9% (p= 0.08). IL-6 mRNA increased by 32.6% (p=0.02), COMP 
levels increased by 12.6% (p=0.06), and Pentraxin-3 levels decreased by 27.3% 
(p=0.14). MHAQ score decreased by 24.6% (p=0.13), self reported global health 
VAS-score decreased by 33.8% (p=0.13), and pain VAS-score decreased by 34.8% 
(p=0.12). The participants scored themselves better for bodily pain and emotional 
role in SF-36.  
 
CONCLUSION: Ten weeks of HIIT was well tolerated by females with RA and JIA, 
and improved the disease activity, quality of life, and traditionally risk factors for 
cardiovascular diseases. HIIT might be recommended as a safe treatment for 
persons with RA and JIA. 
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1.  Introduction 
1.1 Inflammatory rheumatic diseases 
Inflammatory rheumatic diseases are often just called rheumatism. Rheumatism 
includes more than 100 rheumatic diseases and conditions that affect joints, and is 
typically characterized by pain and stiffness in or around one or more joints in 
addition to systemic symptoms such as fever, fatigue and loss of energy (Hunder, 
2001, Brady et al., 2003). The pattern, severity and location of symptoms can vary 
depending on the specific form of the disease. The symptoms can develop gradually 
or suddenly, and the rheumatic conditions most often decrease the quality of life and 
function. The disease has a significant impact on a nation’s economy in terms of 
great amounts and/or expensive medication, as well as hospitalization (Hunder, 
2001). Rheumatism and its related musculoskeletal disorders constitute the most 
common chronic illness in the western world (Hunder, 2001). Arthritis and other 
rheumatic conditions are an important and growing health problem, whether 
measured in terms of prevalence, disability or costs (Brady et al., 2003). This study 
focuses on subjects with rheumatoid arthritis (RA), the most common inflammatory 
rheumatic disease, and juvenile idiopathic arthritis (JIA) among adults. 
 
1.1.1 Rheumatoid arthritis (RA) 
RA is the most common inflammatory arthritis, affecting approximately 0.5-1% of the 
world’s population (Alamanos et al., 2006). The incidence varies by age, race and 
geographic location, and females are affected 3-times more often than males 
(Hunder, 2001). The cause of RA is unknown, but there is strong evidence that the 
disease occurs in genetically predisposed individuals, probably after exposure to one 
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or several yet unknown antigens (Hunder, 2001). There are probably multiple genetic 
factors involved, and the disease involves a complex interplay of genotype, 
environmental triggers and chance (McInnes and Schett, 2011). RA is classified as a 
chronic, systemic, autoimmune disease. The major symptoms are synovial 
inflammation and swollen joints, autoantibody production, deformation of cartilage 
and bone structures, and systematic features such as cardiovascular, pulmonary, 
psychological and skeletal disorders (McInnes and Schett, 2011). The 1987 
American College of Rheumatology (ACR) criteria has until very recently been used 
in order to classify patients. For the diagnosis of RA a patient must fulfill 4 out of 7 
criteria: Morning stiffness ≥1 hour, arthritis of ≥3 joints areas, arthritis of hand/wrist 
joints, symmetrical arthritis, rheumatic nodules, serum rheumatoid factor (RF) and 
radiographic changes (Arnett et al., 1988). The new classification system published in 
2010 redefines the current paradigm of RA by focusing on features at earlier stages 
of disease that are associated with persistent and/or erosive disease, rather than 
defining the disease by its late-stage features (Table 1). To be classified as having 
RA, patients must have synovitis > 1 joint, absence of alternative diagnosis that 
better explain the synovitis, total score ≥ 6 from the individual scores in 4 domains 
(Aletaha et al., 2010).  
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Table 1.1: The 2010 American College of Rheumatology/European League Against Rheumatism 
classification criteria for RA 
 Score 
Target population (Who should be tested?): Patients who 
1) have at least 1 joint with definite clinical synovitis (swelling) 
2) with the synovitis not better explained by another disease 
 
 
 
Classification criteria for RA (score-based algorithm: add score of categories A-
D; a score of ≥6/10 is needed for classification of a patient as having definite 
RA) 
A. Joint involvement 
1 large joint  
2−10 large joints  
1−3 small joints (with or without involvement of large joints)  
4−10 small joints (with or without involvement of large joints)  
>10 joints (at least 1 small joint)  
B. Serology (at least 1 test result is needed for classification) 
Negative RF and negative ACPA  
Low-positive RF or low-positive ACPA  
High-positive RF or high-positive ACPA  
C. Acute-phase reactants (at least 1 test result is needed for classification) 
Normal CRP and normal ESR 0  
Abnormal CRP or normal ESR 1  
D. Duration of symptoms 
<6 weeks  
≥6 weeks  
 
 
 
 
 
0 
1 
2 
3 
5 
 
0 
2 
3 
 
0 
1 
 
0 
1 
 
RF= Rheumatoid Factor, ACPA= Anti Cyclic Citrullinated Peptide Antibodies, CRP= C - reactive 
protein, ESR= Erythrocyte Sedimentation Rate. (Aletaha et al., 2010) 
 
 
1.1.2 Juvenile idiopathic arthritis (JIA) 
Juvenile idiopathic arthritis (JIA) is not a single disease, but a term that encompasses 
all forms of arthritis that begin before a person is 16 years of age, that persist for 
more than 6 weeks, and are of unknown origin. It is the most common chronic 
rheumatic disease in children and causes much disability. In high-income countries it 
has a yearly incidence of 2-20 cases per 100.000 and a prevalence of 16-150 cases 
per 100.000 (Prakken et al., 2011). JIA is not only a disease of childhood, as more 
than a third will continue to have active disease as adults (Foster et al., 2003). As 
children who have JIA reach adulthood, they face possible continuing disease 
activity, medication-associated morbidity, and life-long disability and risk for 
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emotional and social dysfunction (Moorthy et al., 2010). The disease is poorly 
described in adult patients, and there is not much literature dealing with adult JIA. 
The JIA-patients do not receive the same focus and attention as RA patients, due to 
absence of research and understanding of the disease. There are few adolescent JIA 
clinics, and there is a need to develop care services with the aim of improving the 
long-term global outcome of JIA (Foster et al., 2003).  
 
 
1.2 Molecular mechanisms associated with RA/JIA 
The pathogenesis of RA and JIA implicates involvement of various cellular 
populations strictly connected by an intricate web of cytokines, chemokines, and 
growth factors leading into cartilage destruction and bone damage (Perricone et al., 
2011). JIA is poorly described in the literature, RA, however, is given more attention. 
About 50% of the risk of developing RA is attributable to genetic factors, and more 
than 30 genetic regions are associated with the disease (Scott et al., 2010). Genome-
wide analyses make it clear that immune regulatory factors underlie the disease 
(Scott et al., 2010). Human lymphocyte antigens (HLA) are strongly associated with 
RA-patients, especially HLA-DRB1, which has been established as a marker gene 
(Adebajo, 2010). Alleles that contain a common amino acid motif in the HLA-DRB1 
region, termed the shared epitope, confer particular susceptibility (McInnes and 
Schett, 2011). HLA are only associated with patients who have positive Rheumatoid 
Factor (RF-positive) or have antibodies against citrullinated antigens (anti-CCP-
/ACPA-positive). Genetic risk factors for ACPA-negative disease appear to be no less 
important than for ACPA-positive disease. However, they are less well established 
and involve different HLA alleles, regulatory factors and lecithin-binding proteins. 
Patients with ACPA-positive disease have a less favorable prognosis than those with 
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ACPA-negative disease (McInnes and Schett, 2011). Many cellular and chemical 
markers have been studied aiming to find a solution for autoimmunity. The activated 
T-cell is believed to be the key effector cell, which orchestrates the immune response 
and mediate a release of cytokines. The key cytokines involved in the pathogenesis 
of RA are Tumor Necrosis Factor-alpha (TNF-α), interleukin-1 (IL-1) and interleukin 6 
(IL-6) (Adebajo, 2010). The mechanisms of JIA are not well described. JIA comprises 
a heterogeneous group of diseases with distinct subtypes, and all subtypes have 
different phenotypes, course and prognoses. However, JIA-patients respond to the 
same treatment as RA-patients, such as TNF-inhibitors and IL-6-inhibitors, thus the 
underlying mechanisms of adult JIA therefore have to be quite similar to those in RA. 
 
1.2.1 Biomarkers in RA/JIA and cardiovascular diseases 
Biomarkers are quantifiable biological parameters which serve as indices of healthy 
or pathological processes, and also reflect response to pharmacological intervention. 
Biomarkers have the potential to help predict which individual is at risk of developing 
RA, and when the arthritis is present, they can indicate bad prognosis such as 
persistent erosive disease, loss of function or early death (Provan, 2011). 
 
ANA screening (Anti-nuclear antibodies) 
ANA is a group of autoantibodies against constituents in the nucleus. A positive test 
for ANA indicates presence of antibodies against the patient’s own gene products.  
ANA screening is an Enzyme-Linked Immunosorbent Assay (ELISA)-test of seven 
important autoantibodies (IgG), subgroups, which are connected to chronic 
connective tissue diseases and other autoimmune diseases. A low-titer ANA without 
subgroups occur in 1-5% of healthy individuals as well, and increase with age. Of 
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people with RA, 25 % are ANA positive, without presenting any specific subgroups 
(Gran, 2009).  
 
Serum rheumatoid factor (RF) 
Rheumatoid factor (RF) is antibodies against a patient’s own immunoglobulin G 
(IgG). The structure of the antibody class may also be IgM or IgA. About 80% of the 
patients with RA have such autoantibodies (Gran, 2009). The RF was until recently 
considered the most important serological biomarker of RA, but since several other 
inflammatory diseases also give a positive test, RF is now explained as a by-product 
of inflammatory activity (Gran, 2009, Provan, 2011). 
 
Anti Cyclic Citrullinated Peptide Antibodies (Anti-CCP/ACPA) 
Proteins with changed arginine to citrulline are called citrullinated. Antibodies against 
citrullinated antigens (Anti-CCP) are found in 50-70% of patients with RA (Gran, 
2009). Anti-CCP, also called ACPA can be detected many years preceding the onset 
of the disease, and assign nearly 70% risk of developing the disease in patients who 
have a strong family history of RA (Provan, 2011). ACPA seems to be more specific 
and sensitive for diagnosis and seems to be a better predictor of prognostic features 
such as progressive joint destruction than RF. Most, but not all, ACPA-positive 
patients are also RF-positive, and 50-80% of individuals with RA have RF, ACPA, or both 
(Scott et al., 2010). 
 
Tumor necrosis factor alpha (TNF-α) 
TNF-α is the prototype ligand of the TNF superfamily. This molecule plays a central 
role in inflammation and immune system development. TNF-α is also involved in a 
number of pathological conditions, including RA and autoimmunity. It is produced by 
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a wide variety of immune, epithelial, endothelial and tumor cells (Idriss and Naismith, 
2000). TNF-α is considered to be a proinflammatory cytokine. In inflammatory 
diseases TNF-α expression is increased in the affected tissue as a result of innate 
and adaptive immune responses. TNF-α then mediates a variety of direct pathogenic 
effects and induces production of other mediators of inflammation and tissue 
destruction, placing TNF-α at the top of a proinflammatory cytokine cascade. Since 
TNF-α is at the top of the cascade, many of the hallmarks of chronic inflammation are 
reduced by TNF-α antagonist therapy (Tracey et al., 2008). Blockade of actions from 
TNF-α by the human TNF-α receptor 2-immunoglobulin constant region fusion 
protein, etanercept, resulted in the first success of biological-response-modifying 
therapy in RA. Since then, monoclonal antibodies to human TNF-α have come into 
use. These agents have been demonstrated to be effective in the treatment of RA in 
clinical, radiological and laboratory settings, particularly when used in combination 
with Methotrexate (Adebajo, 2010). 
 
Human pentraxin 3 (PTX3) 
Pentraxin 3 (PTX3), also known as Tumor necrosis factor-stimulated gene 14 (TSG-
14), is a long pentraxin belonging to the pentraxin superfamily. Unlike the classic, 
short pentraxins, C-reactive protein (CRP) and serum amyloid P components (SAP), 
PTX3 is highly conserved in evolution, and it differs from the short pentraxins by 
presence of an unrelated long N-terminal domain. Short pentraxins are mainly 
produced in the liver in response to inflammatory cytokines, in particular as a direct 
response to interleukin-6 (IL-6) stimulation. PTX3 is produced by a variety of cells in 
response to primary inflammatory signals and Toll-like Receptor (TLR) engagement. 
It increases rapidly in plasma during inflammatory and infectious conditions (Bottazzi 
et al., 2006). PTX3 also has a role in the regulation of the innate immune response, 
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and interacts with selected viral, fungal and bacterial components, providing 
protection from infection and may act as an opsonin (Bottazzi et al., 2006). 
PTX3 is a novel candidate immunoinflammatory marker that has been reported to be 
associated with cardiovascular risk factors and to predict adverse outcomes in 
individuals with CVD (Jylhava et al., 2011). High-intensity training (HIT) shares 
similarities with acute phase responses of inflammatory disease (Nakajima et al., 
2010). Nakajimi and colleges found that plasma levels of PTX3 and high sensitive 
CRP (hsCRP) increased during acute HIT in untrained healthy subjects. Daily regular 
exercise is known to induce anti-inflammatory effects and protect against the risk of 
CVD by decreasing plasma levels of PTX3 and hsCRP. Plasma PTX3, as an 
inflammatory marker, increases acutely during HIT, but decreases  below pre-training 
levels during cardiac rehabilitation, following the improvement of exercise capacity in 
patients with CVD (Fukuda et al., 2011). 
 
C-reactive protein (CRP) 
Among various markers of inflammation, CRP is a powerful predictor of 
cardiovascular diseases (CVD) (Pahor et al., 2006). CRP belongs to the pentraxin 
family of proteins and its production is mainly mediated by IL-6. In pathological 
situations such as inflammation or infections, CRP levels can increase substantially. 
Increased levels of CRP in the high sensitive range (hsCRP) are associated with 
higher risk of cardiovascular morbidity and mortality in the general population 
(Jeppesen et al., 2008). RA patients have often higher CRP/hsCRP levels than 
healthy persons (Dundar et al., 2008). 
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Interleukin 6 (IL-6) 
IL-6 is a multifunctional cytokine involved in the inflammatory response and 
modulation of immune responses, including B-cell and T-cell differentiation. IL-6 is a 
B-cell differentiation cytokine that induces the final maturation of activated B cells into 
immunoglobulin-secreting plasma cells, and is over-expressed in the affected tissues 
of RA patients (Lee et al., 2012). IL-6 appears to be involved in a long series of 
deleterious actions, and it was previous classified as a “bad” interleukin (Fisman et 
al., 2003). New research has found that IL-6, besides its pro-inflammatory properties, 
also has anti-inflammatory activity (Petersen and Pedersen, 2005). Regular physical 
exercise has been shown to promote anti-inflammatory effects by decreasing some 
inflammatory cytokines (Bruunsgaard, 2005). The mechanism by which regular 
exercise reduces inflammation is not completely understood, but IL-6 has been 
shown to be a part of it (Mitchell et al., 2011). IL-6 mRNA is upregulated in 
contracting skeletal muscle, and the transcriptional rate of the IL-6 gene is markedly 
enhanced by acute exercise (Jonsdottir et al., 2000, Keller et al., 2001). The increase 
in circulating levels of IL-6 after exercise is consistent and proportional to exercise 
duration, intensity, muscle mass involved, and endurance capacity (Fischer, 2006, 
Leggate et al., 2010). Physiological concentrations of IL-6 stimulate the appearance 
in the circulation of the anti-inflammatory cytokines interleukin-1 receptor antagonist 
(IL-1ra) and interleukin-10 (IL-10), and inhibit the pro-inflammatory cytokine TNF-α 
(Steensberg et al., 2003, Keller et al., 2004).  
 
Human Cartilage Oligometric Matrix Protein (COMP) 
Human Cartilage Oligometric Matrix Protein (COPM) is a member of the 
Thrombospondin protein family, calcium-binding extracellular glycoproteins. COMP 
has been demonstrated to be a biomarker for cartilage breakdown. COMP is 
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subjected to proteolytic cleavage in the cartilage of patients suffering from arthritis 
(Neidhart et al., 1997, Morozzi et al., 2007). These fragments are detectable in the 
circulation and may serve as diagnostic and prognostic indicators and as biomarkers 
for disease severity and response to treatment (Posey and Hecht, 2008). In rat 
studies serum COMP levels correlate with the degree of cartilage destruction in 
arthritis rats (Vingsbo-Lundberg et al., 1998). In RA, serum COMP levels decreases 
in patients who respond to treatment (Crnkic et al., 2003).  
 
 
1.3 Cardiovascular risk in patients with RA/JIA 
Cardiovascular diseases (CVD) is the global number one cause of mortality, and 30% 
of global deaths are attributed to one or other form of CVD (WHO, 2011). The 
general mortality rate in patients with RA is 1.5 – 1.6 compared to that of the general 
public, and CVD accounts for 40-50% of the deaths (Avina-Zubieta et al., 2008). An 
especially high risk was observed in female patients with RA who were diagnosed at 
a young age. Those being 20-39 years of age at first discharge had a more than 5-
fold increased risk of death from coronary artery diseases (CAD) (Bjornadal et al., 
2002). Patients with RA therefore have a shorter life expectancy compared to the 
general population. Many people die every year from CVD, but in people with RA, 
CVD related death often occurs at an earlier age (Pahor et al., 2006). 
 
Mechanisms underlying increased CVD risk in RA patients are not yet elucidated. RA 
patients may have an unfavourable genetic profile, and there is evidence that they 
are more likely to have a close relative who has suffered from a myocardial infarction 
(MI) (Solomon et al., 2003). Common risk factors for CVD and RA such as smoking, 
lack of physical activity or high body mass index (BMI), which are consequences of 
RA and risk factors for CVD, may also be of importance (Solomon et al., 2003). 
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Patients with RA have been shown to be at a considerably increased risk of 
developing MI already in the two years prior to fulfilling the 1987 American College of 
Rheumatology (ACR) diagnostic criteria for RA (Maradit-Kremers et al., 2005). RA 
itself is an important risk factor for early atherosclerosis, demonstrated by intima-
media thickness (IMT) and plaque formation (Pahor et al., 2006). Carotid artery IMT 
is associated with cardiovascular risk factors and atherosclerosis and is a strong 
predictor of MI and stoke (Pahor et al., 2006).  
 
 
1.4 Treatment of RA/JIA 
1.4.1  Medication 
Until some decades ago gold-components, sulphasalazine and hydroxychloroquine 
were the preferred treatment drugs for RA (Provan, 2011). However, the introduction 
of Methotroxate (MTX) in the 1980’s did indeed bring great changes to the treatment. 
More than a decade later, in the late 1990 and start of year 2000, the introduction of 
TNF-α inhibitors further enhanced the treatment of RA. TNF-α inhibitors, termed 
biologic treatment, is given to the patients that do not have sufficient effect of MTX. 
The last years other biologic treatments targeting cytokines or molecules involved in 
the RA disease have become available, such as antibodies against IL-1 and IL-6, 
antibodies against B-cells and T-cells modulators (Hoff, 2009). TNF-α inhibitors are 
now, in combination with MTX, the most effective drug treatment for patients with RA 
(Seymour et al., 2001, Barrera et al., 2002).  
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1.4.2 Exercise 
Not more than 10-20 years ago, patients with arthritis were told to rest and to avoid 
exercise involving the affected joints (Brady et al., 2003, Baillet et al., 2010). Now the 
recommendations are different. RA-patients are told to exercise 4-7 days a week with 
moderate intensity aerobic activity such as cycling, cross-country skiing, walking, 
pool training, dance or strength training with low weights (Helsedirektoratet, 2009). 
Scientific studies have shown that regular physical activity is just as important for 
people with arthritis or other rheumatic conditions as it is for the general population 
(Brady et al., 2003, CDC, 2011). Participation in physical moderate-intensity activities 
improves pain, function, mood, and quality of life without worsening symptoms or 
disease severity. Being physically active can also delay the onset of disability in 
patients with arthritis (CDC, 2011, Baillet et al., 2010). However, literature on the 
effect of exercise at high intensity in this patient group is sparse. Several studies 
have indicated that aerobic interval training (AIT) with high intensity is effective in 
improving general physical status and cardiovascular health in people with and 
without CVD (Tjonna et al., 2009, Wisloff et al., 2007).  
 
 
1.5 The aim of the study 
 
The primary aim of this study was to investigate if 10 weeks of high intensity interval 
training influenced the disease activity in patients with RA and JIA, and to find out if 
high-intensity aerobic exercise can be considered safe and used as therapy in stabile 
RA/JIA.  
 
Since inflammatory rheumatic diseases increase the risk for CVD, and the mortality 
rate in patients with RA and JIA is higher compared to that of the general public, the 
secondary aim of this study was to investigate how HIIT is affecting cardiovascular 
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risk factors in RA/JIA patients. This study also aimed to elucidate if HIIT improved 
outcomes in function, quality of life and pain in patients with RA and JIA. 
 
Hypothesis  
Ten weeks of high intensity interval training will be well tolerated by RA and JIA 
patients, and will improve the disease activity, quality of life, and traditionally risk 
factors for CVD.  
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2.  Methods and experimental procedures 
2.1 The study 
2.1.1 Subjects 
Eighteen women with RA and JIA, aged 20-50 years, were recruited through 
advertising in a local newspaper (Adresseavisen), via the webpage at NTNU, and via 
notes in Department of Rheumatology at St. Olavs Hospital, Trondheim. Before 
inclusion a rheumatologist ensured that the subjects were qualified, with correct 
diagnosis, stable health and were free of other complications. The exclusion criteria 
were heart disease, lung disease, or unstable disease. All subjects provided written 
informed consents. The regional committee for medical research ethics approved the 
protocol (REK 2010/3347). 
 
2.1.2 Study design 
This was a cross-over study, meaning that the participants were their own controls for 
the effect of the intervention. The participants were randomized into two different 
groups; interval training or control. The randomisation was carried out by The Clinical 
Research unit at NTNU. It was stratified for RA and JIA, to secure equal numbers of 
both diseases in both groups. After the first period of either training or control, the 
participants had a two months “washout-period”. Then the groups changed place, 
crossed over, so that the first training group became the new control group, and the 
first control group became the new training group (Figure 2.1). In the control period the 
subjects were instructed to live their lives as normal. All measurements and tests were 
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conducted pre and post the 10 weeks of either interval training or control-period, a 
total of 4 tests for each person. 
 
 
Recruited
n = 18
HIIT-group 1
n = 9
Control-
group 1
n = 9
Analyzed
HIIT
n = 6
Analyzed
controls
n = 9
Control-
group 2
n = 6
HIIT- group 
2
n = 7
Drop out
n = 3
- 2 changed
medication
- 1 got bad knee
Analyzed
controls
n = 6
Analyzed
HIIT
n = 6
Drop out
n = 0
- 1 moved out of
the region
- 1 in again after
stabile 
medication
Drop out
n = 2
- 2 moved out of
region
Drop out
n = 1
- 1 got pregnant
2 months
washout-period
Total: 12 participants finished the HIIT-period. 15 partisipants finished the control-
period. 11 participants did both HIIT and control period.
 
Figure 2.1: Flow chart of the study design.  
n = numbers of subjects, HIIT = high intensity interval training. 
 
 
2.2  Characteristics and fitness of the participants 
2.2.1 Maximal oxygen uptake and heart rate 
The subjects’ maximal oxygen uptake (VO2max) was tested by using the ergospirometry 
system Oxycon Pro (Jaeger, Oxycon Pro, Hoechberg, Germany). An individually 
adjusted test bike (Monark 839 E, Monark Exercise AB, Sweden) was used. During 
warm-up the resistance of the bike was individually adjusted, based on the subject’s 
fitness level. After the 10 min warm-up the test started by increasing the resistance of 
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the bike. The resistance was increased by 20 watts every time the level of the oxygen 
uptake stabilised, meaning approximately once every minute. This was done until 
exhaustion. The best way to ensure that the true VO2max was reached, was to see that 
the oxygen (O2) curve had a straightening out or drop, in spite of increased resistance 
of the bike. This, in combination with a respiratory exchange ratio (volume of exhaled 
carbondioxide (CO2) divided by volume of inspired O2 per minute) higher than 1.05, 
was used as criteria for true VO2max. 
 
Knowing the individual’s maximal heart rate (HRmax) was necessary since the intervals 
during 10 weeks of exercise training were to be performed at an intensity of ~90% of 
HRmax. The heart frequency was registered continuously during the VO2max-test using a 
heart rate monitor (Polar Electro, Kempele, Finland). The highest heart rate during the 
test was ascribed 5 additional beats, to find the HRmax. When the HRmax was obtained 
it was used to calculate individual heart rate at which exercise was to be performed. 
After stopping at exhaustion the subjects were told to sit still on the bike for one 
minute, and the one-minute heart rate recovery (1-minHRR) was found by measuring 
the heart rate one minute after the end of the test.  
  
2.2.2 Blood pressure 
Blood pressure was measured at pre- and post-testing using sphygmomanometer 
Microlife BPA 100 Plus (Microlife AG, 9435 Heerbrugg, Switzerland). The 
sphygmomanometer used had an integrated stethoscope, and all measurements were 
performed automatically. The subjects rested in a quiet room for about 10 min prior to 
the measurements. The cuff was placed at the upper arm, and it was quickly inflated to 
~200 mmHg, and then the pressure was gradually released. Systolic and diastolic 
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pressures were measured. This was done two to three times, two times if the 
measurements were similar, three times if the variation coefficient was more than 
15%. The first measurement was rejected. The second, or the average of the second 
and third measurements was used. 
 
2.2.3  Body composition 
To assess body fat percentage, muscle mass percentage, weight and BMI, the 
bioelectrical impendence analyzer HBF-352-W (Omron Healtcare Co, Kyoto, Japan) 
was used. Patients were weighed after an overnight fasting, in light clothing and 
without shoes. Body weight was recorded to the nearest 0.1 kg, and body fat 
percentage and muscle mass percentage were measured to the nearest 0.1%. It was 
ensured that the measurements during post-testing were taken at the same time of the 
day as the pre-testing. 
 
 
2.3 Blood analysis 
Overnight fasting blood was taken from the antecubal vein, both at pre and post-test. 
Blood samples taken for the post-test were done 48-96 hours after the last exercise 
session. Blood was collected into both PAXgene (Qiagene, Germantown, MD), EDTA 
and serum tubes (Greiner-Bio One GmbH, Frickenhausen, Germany).  EDTA plasma 
and serum were centrifuged at 3000 rcf for 10 minutes at 20°C. For later analysis the 
serum and plasma were stored at -80°C. The PAXgene tubes were handled according 
to the manufacturer’s instructions. In addition: S-ferritin, triglyceride, total cholesterol, 
HDL-cholesterol, glucose, leukocytes, neutrophil granulocytes, haemoglobin, 
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thrombocytes, high sensitive CRP, eosinophils, basophiles, white blood cell count, 
insulin C-peptide and IGF-1 were analysed at the Department of Medical Biochemistry 
at St. Olavs University Hospital, Trondheim, Norway. 
 
 
2.4 Disease activity 
All patients were examined by a rheumatologist before and after the training and the 
control period. Clinical and demographic data were collected by the treating 
rheumatologists and by patient self-report. Counting of swollen and tender joints was 
performed by the rheumatologist. 
 
2.4.1  Disease activity score (DAS28) 
DAS28 is a measurement of disease activity in RA calculated for a total of 28 joints. 
The score is calculated by a complex mathematical formula, which includes the 
number of tender and swollen joints (out of a total of 28), the patient’s VAS-score for 
global health (indicated by marking a 10 cm line between very good and very bad), 
and the erythrocyte sedimentation rate (ESR, a blood marker of inflammation) or the 
CRP rate.  In this study CRP levels were used, since the CRP is a more sensitive and 
direct measurement of inflammation than ESR (Crowson et al., 2009). High disease 
activity is defined as DAS28 >5.1, moderate disease activity between 3.2-5.1, and low 
disease activity is below 3.2 (Prevoo et al., 1995). 
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DAS28 was calculated from the following formula: 
DAS28-CRP = 0.56*√(TJC28) + 0.28 *√(SJC28) + 0.36*ln(CRP+1) + 0.014*GH + 0.96 
TJC28: 28 Tender joint count; SJC28: 28 Swollen joint count; CRP: C-reactive protein (mg/l); GH: 
General Health on a 100mm Visual Analogue Scale (VAS). 
 
2.4.2 Questionnaires  
Visual analogue scales (VAS) 
VAS has been used in the social and behavioral sciences to measure a variety of 
subjective phenomena. A VAS is a straight line, whose end anchors indicate the 
extreme boundaries of the sensation, feeling, or responses to be measured. For 
example a VAS to measure pain could be labeled “no pain” on one end and “pain as 
bad as it could possibly be” on the other end. Subjects respond to the VAS by placing 
a mark through the line at a position which best represents their current perception of 
a given phenomenon between the labeled extremes. Although a VAS may be 
horizontal or vertical and of any length deemed appropriate, its most common form is a 
100 mm horizontal line. The VAS is scored by measuring the distance, usually in 
millimeters, from one end of the scale to the subject’s mark on the line (Wewers and 
Lowe, 1990). In the present study, a score from 1-100 was used for measuring self 
reported global health, total pain and fatigue. While a score from 1-18 was used for 
self reported joint pain. 
 
Modified Health Assessment Questionnaire (MHAQ) 
Patient satisfaction in performing activities of daily living (ADL) was assessed by using 
a self-administered questionnaire modified from the Stanford Health Assessment 
Questionnaire (MHAQ). The MHAQ includes questions to determine a patient's degree 
of difficulty and need for help and assistive devices in ADL. The patients answer if they 
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have difficulty performing ADL from 0= no difficulty; 1= some difficulty; 2= much 
difficulty, and 4 is unable to do (Pincus et al., 1983). 
 
SF-36 
The patients also answered the medical outcome study 36-item short form survey (SF-
36) The SF-36 consists of eight scaled scores, which are the weighted sums of the 
questions in their section. Each scale is directly transformed into a 0-100 scale on the 
assumption that each question carries equal weight. The eight sections are; vitality, 
physical functioning, bodily pain, general health perceptions, physical role functioning, 
emotional role functioning, social role functioning, and mental health. 
 
 
2.5 Molecular analysis 
 2.5.1 Enzyme-linked immunosorbent assay (ELISA) 
The ELISA technique can detect an amount of a given protein, antibody, or antigen in 
a fluid sample. Plasma levels of TNF-α were measured before and after both the 
exercise and control periods by Quantikine Human TNF-α Immunoassay kit (R&D 
Systems, Minneapolis, USA). Plasma levels of Pentraxin 3 were measured before and 
after both the exercise and control periods by Quantikine Human Pentraxin 3/TGS-14 
Immunoassay kit (R&D Systems, Minneapolis, USA). Serum levels of COMP were 
measured before and after both the exercise and control periods by Quantikine Human 
COMP Immunoassay kit (R&D Systems, Minneapolis, USA).  All samples were treated 
according to the manufacturer’s instructions, and the analyses were automated and 
performed by use of a DS2 Two-plate Automated ELISA Processing System (Dynex 
Technologies, Chantilly, USA). 
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2.5.2 Isolation of RNA from full blood 
DNA is stored in a cells nucleus, and since only the white blood cells have nucleus, 
they contain DNA. DNA is transcribed to messenger RNA (mRNA), which again are 
translated to specific proteins. At a given time, the mRNA level encoding different 
proteins reflects the cellular response to different stimuli. In this study, RNA was 
isolated from whole blood, collected in PAXgene tubes (Qiagene, Germantown, MD). 
Total RNA was isolated using the PAXgene Blood RNA Kit (Qiagene, Germantown, 
MD) according to the manufacturer’s protocol (Blood RNA Kit Handbook, version 2), 
and the analyses were done automatically in QIAcube (Qiagene, Germantown, MD). 
To ensure high mRNA quality and purity all samples was measured on a Nanodrop 
2000, NanoDrop Technologies, Baltimore, MD). The Nanodrop instrument applies 
ultraviolet spectrophotometry at 260/280 nm to assess the concentration and quality of 
total RNA in the sample. Only samples with a 260/280 ratio > 1.8 were used for further 
analysis. 
 
2.5.3  Real-time quantitative polymerase chain reaction (Real-time qPCR) 
 Reverse transcriptase PCR is also called quantitative PCR (qPCR). Traditional PCR 
is used for end-point analysis to distinguish gene products. In real-time qPCR, the 
amount of PCR product is measured at each cycle. The amount of RNA is measured 
by the use of fluorescent markers that are incorporated into the PCR product. This 
ability to monitor the reaction during its exponential phase enables users to determine 
the initial amount of target with great precision. One step qPCR combines the first-
strand cDNA synthesis reaction and qPCR in the same tube. In multiplex real-time 
PCR more than one set of gene-specific primers are used to amplify separate genes in 
a single tube. Typically, multiplex reactions are used to amplify the gene of interest 
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and a housekeeping gene. Different fluorescent reporter dyes are used to label and 
distinguish the separate primers or probes for each gene.  
 
Isolated RNA from before and after the exercise period was used to determine the 
levels of IL-6 by using one-step multiplex real-time qPCR. The analysis was done by 
using the Hs-IL6-1-FAM QuantiFast Probe Assay, One-step RT-PCR, Duplex kit 
(Qiagen, Germantown, MD) according to the manufacturer’s instructions (QuantiFast 
Probe Assay Handbook 05/2011). The reference gene was Hs-B2M-2-Max. The 
analysis was performed by the use of the Bio-Rad, CFX 96 Real-Time system (Bio-
Rad laboratories Ldt., UK). 
 
 
2.6 Exercise training protocol 
Participants performed supervised exercise training 2 times a week for 10 weeks on a 
spinning bike. Individual speed and resistance of the bikes were adjusted to fit the 
participant’s fitness level. The exercises started with a warm-up for 10 minutes at 
~70% of HRmax followed by four 4-minute intervals at ~90% of HRmax, interspersed with 
3 minute recovery periods at ~70% of HRmax. Total exercise duration was 40 minutes. 
All subjects used a heart rate monitor (Polar Electro, Kempele, Finland) during all 
exercise sessions to ensure that the assigned exercise training intensities were 
obtained. The speed and resistance of the bike was adjusted continuously to ensure 
that each exercise session was carried out at the assigned intensity throughout the 
exercise training period. The HIIT program “4x4”, is found to be an interval program 
that most people are able to manage, despite their fitness level (Helgerud et al., 2007).  
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2.7  Statistical analyses 
Statistical analyses were performed using the software program SPSS, version 19.0 
(SPSS Inc.). Means and standard deviations (SD) for all variables were computed 
using descriptive statistics. All values are expressed as mean ± SD. All tests had a 
significant level set to p ≤ 0.05. Trend levels were set to p ≤ 0.15. Figures were made 
using GraphPad (GraphPad Prisma 5, LaJolla, CA, USA). To test the normality of the 
data, the Smirnov Kolmogorov test was used. All the data were found to have normal 
distribution. The values at the start of a period (pre values) and the values at the end 
of the period (post values) for the different variables were used for calculating the 
significant change in variables during the ten week period. Paired Student’s T-test was 
used for pre/post comparisons. Linear mixed model was used for calculating the group 
comparisons of the study. This type of analysis was used since the same subjects 
were both the training and the control group, just switching places. Not exactly the 
same subjects were in both training and control group, and the groups did not have 
equal numbers participants. There were also some drop-outs after the study 
commenced. The linear mixed model used, took all this into account, making it 
possible to compare the effect of training to the control group.  
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3.  Results 
3.1 Characteristics and fitness of the participants  
Baseline characteristic of all the participants are shown in Table 3.1. Nearly all of them 
were treated for their disease with medication, but only 38.9% of them used TNF-α 
inhibitors as medication. Disease modifying anti-rheumatic drugs (DMARD) was used 
by 72.2% of the participants.  
 
Table 3.1: Baseline characteristics for the 18 participants in the study. 
 
Variables Value 
Age, yr 34±8 
Height, cm 167.3±5.6 
RA diagnoses 7 
JIA diagnoses 11 
ACPA positive 7 
RFIgM positive 6 
ANA positive 1 
Erosions in hands/feet, positive 7 
Uses DMARD 13 
Uses antiTNF-α medication 7 
Smokes 3 
Values for age and height are presented as mean ± SD, RA=Rheumatoid Arthritis, JIA=Juvenile 
Idiopathic Arthritis, ACPA= Anti Cyclic Citrullinated Peptide Antibodies, RFIgM= Rheumatoid Factor for 
immunoglobulin M, ANA= Anti-Nuclear Antibodies, DMARD= Disease Modifying Anti-rheumatic Drugs, 
TNF-α= Tumor Necrosis Factor-alpha 
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3.1.1 Maximal oxygen uptake and heart rate 
VO2max increased with 12.2% ±0.4 during the exercise period (p < 0.001). There was 
no significant difference from pre to post in the control period (Figure 3.1). The group 
difference between the HIIT and the control periods was significantly different  
(p < 0.001). The 1-minHRR decreased 3.7% ±0.2 after HIIT (p = 0.02), whereas no 
changes were observed during the control period (Table 3.2.B).  
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Figure 3.1: VO2max pre (white) and post (black) in HIIT and control group.   
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Figure 3.2: HRmax (A) and 1-minHRR (B) in HIIT and control group, pre-tests in white, post-tests in 
black.  
HRmax: maximal heart rate, 1-minHRR: one minute heart rate recovery, HIIT: high intensity interval 
training. 
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3.1.2 Blood pressure 
No significant differences were observed from pre to post-tests in either the HIIT or the 
control period, and no significant differences were observed between the groups 
(Table 3.2). 
 
 
Table 3.2: Systolic and diastolic blood pressure in the HIIT and control group, and calculation for 
the group difference between HIIT and control. 
 
 HIIT group Control group  Group differences 
 pre post pre post p-value 
Systolic BP 
(mmHg) 
 
120.7±9.6 118.8±11.4 120.0±14.0 116.6±9.4 0.57 
Diastolic BP 
(mmHg) 
73.7±7.5 73.1±7.0 73.5±10.2 73.8±10.2 0.82 
Values presented as mean ± SD, HIIT=high intensity interval training, BP=blood pressure. 
 
 
 
3.1.3  Body composition 
In the HIIT group, BMI, body fat, visceral fat and waist circumference decreased by 
1.2% (p= 0.04), 1.0% (p= 0.05), 0.2% (p= 0.08) and 1.6% (p= 0.004) respectively, after 
the exercise period. HIIT resulted in an increase in percent muscle mass from 26.4 to 
27.0% (p= 0.03) within the same group. No significant differences were found in the 
control period (Table 3.3).  
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Table 3.3: Physiological parameters in the HIIT and control group, and calculation for the group 
difference between HIIT and control. 
 
 HIIT group Control group Group differences 
 pre post pre post p-value 
Weight (kg) 70.5±14.6 69.8±14.0 67.7±15.0 67.4±13.7 0.56 
BMI (kg/m2) 24.8±4.9 24.5±4.6* 24.0±4.3 24.2±4.9 0.05* 
Body fat (%) 36.9±9.1 35.9±9.5* 35.5±8.5 35.1±8.1 0.18 
Visceral fat (%) 5.5±2.6 5.3±2.6# 5.0±2.4 5.1±2.5 0.02* 
Muscle mass (%) 26.4±3.9 27.0±4.2* 26.8±3.7 27.0±3.4 0.08# 
Waist (cm) 89.5±12.0 88.1±11.2* 86.2±12.9 85.9±12.2 0.07# 
Values presented as mean ± SD, HIIT=high intensity interval training, BMI=body mass index,  
* p≤0.05,  
#
 0.05<p<0.15. 
 
 
 
3.2 Blood analysis 
In the HIIT group, glucose increased by 6.3% (p= 0.05), haemoglobin decreased by 
2.2% (p= 0.03), and ferritin decreased by 24.0% (p= 0.006) after the exercise period. 
The hsCRP level decreased by 41.9% (p= 0.08) from pre to post in the HIIT period. No 
significant differences were found for insulin C-peptide, IGF-1, HDL-cholesterol, 
cholesterol, triglyceride, leucocytes, neutrophile granulocytes, thrombocytes, 
eosinophiles, or white blood cell count, either in the HIIT or the control period  
(Table 3.4).  
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Table 3.4: Blood variables in the HIIT and control group, and calculation for the group difference 
between the HIIT and control group. 
 
 HIIT group Control group Group differences 
 pre post pre post p-value 
hsCRP (mg/l) 2.89±2.77 1.68±1.19
#
 2.75±2.31 2.79±1.84 0.37 
Insuline C-peptides 
(nmol/l) 
0.59±0.24 0.62±0.29 0.66±0.29 0.62±0.22 0.54 
IGF-1 (nmol/l) 27.2±9.5 23.4±7.6 26.7±9.9 26.0±10.1 0.22 
Glucose (mmol/l) 4.75±0.44 5.12±0.55* 4.86±0.44 4.53±0.47* 0.05* 
HDL-cholesterol 
(mmol/l) 
1.52±0.47 1.50±0.42 1.62±0.52 1.59±0.53 0.88 
Cholesterol (mmol/l) 4.78±1.11 4.79±1.08 4.83±1.09 4.71±0.96 0.86 
Haemoglobin (g/dl) 13.9±0.9 13.6±1.1* 13.6±0.9 13.6±1.0 0.22 
Ferritin (μg/l) 78.8±69.6 59.9±54.3* 63.6±41.6 66.8±52.5 0.06
#
 
Triglyceride (mmol/l) 0.91±0.42 0.95±0.52 1.04±0.56 1.01±0.64 0.96 
Leucocytes (10
9
/l) 6.33±2.07 6.58±1.66 6.16±1.42 6.42±1.98 0.94 
Neutrophile 
granulocytes (10
9
/l) 
3.88±1.69 3.88±1.21 4.10±1.05 4.98±1.79 0.58 
Thrombocytes (10
9
/l) 235.2±27.9 223.4±24.7 242.8±30.2 233.3±29.1 0.70 
Eosinophiles (10
6
/l) 200.0±185.9 185.6±114.6 240.0±240.8 186.7±146.7 0.63 
      
Values presented as mean ± SD, HIIT=high intensity interval training, hsCRP=high sensitive CRP,  
IGF-1=insulin growth factor 1, HDL=high-density lipoprotein, * p≤0.05, 
#
 0.15<p<0.05  
 
 
3.3 Disease activity 
 
MHAQ score decreased by 24.6% ±1.6% during HIIT (p=0.15), and the change tends 
to be different from the change in the control period (p=0.13). Self reported global 
health VAS-score decreased by 33.8% ±1.5% (p=0.134) during the HIIT, with no 
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difference between the groups. Total pain score did show a decreasing trend when 
comparing the groups (p=0.12). The fatigue score did not change during HIIT, but 
decreased significantly during the control period (p=0.03) (Table 3.5).  
 
 
Table 3.5: Disease activity in the HIIT and control group, and calculation for the group difference 
between HIIT and control. 
 
 HIIT group Control group Group differences 
 pre post pre post p-value 
DAS28 2.56±0.94 2.29±0.58 2.48±0.93 2.48±0.64 0.44 
MHAQ 0.65±0.43 0.49±0.45# 0.42±0.41 0.50±0.49 0.13# 
Self reported health score 32.0±20.7 21.2±18.6# 26.0±20.4 25.2±17.3 0.26 
Self reported joint pain 2.45±2.34 2.36±1.86 3.08±2.29 3.46±2.26 0.56 
Pain score 30.2±23.1 19.7±20.0 24.3±20.6 28.0±19.6 0.12# 
Fatigue score 39.2±30.2 39.3±28.2 40.1±31.2 26.2±26.3* 0.21 
Values presented as mean ± SD, HIIT=high intensity interval training, DAS28=Disease Activity Score 
from 28 joints, MHAQ=Modified Health Assessment Questionnaire,  * p≤0.05,  
#
 0.05<p<0.15  
 
 
SF-36 
According to the questionnaire SF-36, there was a trend towards that the participants 
felt less pain and they had better emotional status after HIIT (Figure 3.3). No such 
difference was seen in other of the categories or in the control period. 
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Figure 3.3: A radar-plot for the questionare SF-36. Totally 36 questions were answered and 
categorisied into 8 groups. Higher score is equal with better health.  
 
3.4 Molecular analysis 
3.4.1  IL-6 
Real-time qPCR showed that expression of IL-6 mRNA increased with 32.6% (p=0.02) 
after HIIT (Figure 3.4). 
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Figure 3.4: Quantitative gene-expression of IL-6 pre (white) and post (black) HIIT. Gene-
expression was performed with RT-qPCR from whole-blood taken from participants pre and post 
10 weeks of HIIT. The IL-6 expression increased significantly with 32.6% (p=0.02).  
IL-6: Interleukin-6. 
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3.4.1  ELISA results 
The ELISA analysis of COMP and Pentraxin-3 did not show any significant differences 
for either HIIT or control period, but the group differences had a trend to increase for 
COMP, and decrease for Pentraxin-3 (Table 3.6). Most of the TNF-α values were 
below the detection limit of the ELISA kit, making it impossible to calculate group 
differences (data not shown).  
 
Table 3.6: ELISA results in the HIIT and control group, and calculation for the group difference 
between the HIIT and control group. 
 HIIT group Control group Group differences 
 pre post pre post p-value 
COMP (ng/ml) 114.5±55.3 128.9±52.1 122.6±62.8 110.4±54.9 0.06# 
PTX-3 (ng/ml) 0.22±0.20 0.16±0.16 0.18±0.12 0.21±0.22 0.14# 
Values presented as mean ± SD, HIIT=high intensity interval training, COPM=Human Cartilage 
Oligometric Matrix Protein, PTX-3=Pentraxin-3,  * p≤0.05, 
#
 0.05<p<0.15  
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4.  Discussion 
The main findings of the present study were that the participants had less pain, felt 
better, and had reduced several risk factors for CVD. In addition, 10 weeks of high 
intensity interval training was well tolerated and there was no increase in disease 
activity or inflammation.  
 
4.1 Characteristics and fitness of the participants 
4.1.1  Maximal oxygen uptake and heart rate 
As expected, the VO2max increased during the exercise period. It has previously been 
shown that HIIT is effective in improving VO2max (Helgerud et al., 2007). 
Cardiorespiratory fitness measured as VO2max or peak oxygen uptake (VO2peak) may 
be the single best predictor of cardiovascular morbidity and premature cardiovascular 
mortality (Aspenes et al., 2011), and low VO2max is clearly associated with a clustering 
of cardiovascular risk factors (Aspenes et al., 2011). Keteyian and colleges even found 
that 1 ml/kg/min increase in VO2peak was associated with an approximate 15% 
decrease in risk for all-cause and CVD-specific mortality (Keteyian et al., 2008). Since 
aerobic training causes the heart’s stroke volume to increase during both exercise and 
rest, it also reduces the heart beats per minute in rest (McArdle, 2010). Slow heart rate 
recovery (HRR) is associated with an increased risk of all-cause death in individuals 
without CVD, and slow HRR may therefore be regarded as an independent risk factor 
for mortality (Wandell et al., 2010). Slow and abnormal HRR is also associated with 
inflammatory markers, which could contribute to the high incidence of cardiovascular 
disease in these subjects (Jae et al., 2007). The 1-minHRR in this study decreased 
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significantly during HIIT by 3.7%. Since VO2max increased it was the stroke volume that 
must have changed in response to training, since HRmax remained the same. Our 
results might indicate that the participants, since their stroke volume increased, 
decreased the risk for CVD.  
 
4.1.2 Blood pressure 
According to reference values for blood pressure (BP) set by the American Heart 
Association, normal values for systolic BP are < 130 mmHg and diastolic BP < 85 
mmHg. At pre tests both the HIIT and the control groups had normal blood pressure. 
High BP is associated with risk for CVD, and exercise has been  shown to lower BP in 
individuals with high BP (McArdle, 2010). Since the participants in this study had 
normal BP initially, no improvements were expected or shown.  
 
4.1.3  Body composition 
In the present study there was no focus on dieting or food intake, and no significant 
decrease regarding weight was found. Significant changes were seen in the BMI, total 
body fat, visceral fat, muscle percent, and waist circumference (WC). According to the 
standards set by the National Institutes of Health, healthy weight is indicated by a BMI 
between 19 and 25 (NIH, 2010). However, recent studies show that the lowest death 
rates occurred in women with BMI in the range of 22.0 to 23.4 (McArdle, 2010, Fox, 
2011). In this study mean values for BMI were measured to be in the range 24.0 to 
24.8, also under the definition of overweight (BMI>25), but over the range for the 
lowest death rates. BMI over 25 is a risk factor for CVD, but the distribution of fat in the 
body is also important. There is a greater risk of CVD when a high amount of visceral 
fat is present (Fox, 2011). Visceral fat is the fat in the mesenteries and greater 
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omentum. While the BMI is a measurement for total body fat, WC is a measurement of 
visceral fat, since visceral fat is stored in the abdominal cavity. Both BMI and WC are 
predictors of CVD, and they may independently contribute to the prediction of total, 
non-abdominal, abdominal subcutaneous, and visceral fat (Janssen et al., 2002). 
Recent studies have suggested that WC might be an even better predictor of mortality 
risk than BMI, since people with normal BMI might have an increased WC (Koster et 
al., 2008, Leitzmann et al., 2011). The participants in this study decreased both total 
body fat and visceral fat after the exercise period, indicating a lowered risk for CVD. 
An increase in muscle mass percentage will result in higher energy consumption, 
meaning that the participants in this study might used more energy daily after the HIIT 
than before. Increased daily energy consumption may help keep the total body fat, and 
also BMI and WC, within healthy range.  
 
 
4.2 Blood analysis 
The blood variables measured in the present study were either variables affecting 
disease activity for RA/JIA, or variables indirectly associated with the risk of 
developing CVD. At the beginning of the study, mean values for all variables were 
within the reference values set for the specific variables. The results indicated that for 
some of the blood variables, the HIIT intervention was sufficient to start a regulation 
towards more preferable values, while the HIIT intervention was insufficient to have 
clinical effect on other variables. 
 
Low-grade chronic inflammation is reflected by increased CRP concentrations and 
increased systemic levels of some cytokines (Ross, 1999). Regular exercise has been 
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proven to protect against diseases associated with low-grade systemic inflammation. 
This long-term effect of exercise may be ascribed to the anti-inflammatory response 
elicited by an acute bout of exercise, which is partly mediated by muscle-derived IL-6 
(Petersen and Pedersen, 2005). In the present study the decrease in hsCRP was not 
significant, but it was a positive trend that the mean values for hsCRP decreased 
during HIIT. People with rheumatic diseases most often have elevated values of 
hsCRP because of joint inflammation (Dundar et al., 2008). Since inflammation plays a 
pivotal role in the pathogenesis of atherosclerosis, elevated levels of  hsCPR are also 
associated with higher risk of cardiovascular morbidity and mortality (Ross, 1999). 
Decrease in hsCRP levels signifies less inflammation and hence lower risk for 
developing CVD.  
 
In the present study both serum ferritin and haemoglobin levels decreased significantly 
after the HIIT. Measurement of serum ferritin is representative of the total body iron 
stores. Reduction of iron status in athletes is well documented (Newhouse and 
Clement, 1988). Both low haemoglobin values and decreased serum ferritin values are 
reported in endurance athletes and even non-endurance athletes exhibit low serum 
ferritin values. One explanation for this might be exercise induced plasma volume 
expansion, making a dilution of the iron components in the serum (Davidson et al., 
1987). Increased iron loss in urine and sweat from athletes is also well documented 
(Newhouse and Clement, 1988, Carlson and Mawdsley, 1986). Measurements of 
fecal, urinary or sweat iron loss were not done in this study. However, this might 
partially explain the loss of iron stores observed after a period of repeated bouts of 
HIIT. High levels of stored iron are associated with inflammatory processes and CVD 
(MacDonald, 1993). During exercise serum ferritin levels, and also iron stores, 
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decrease, and could be one mechanism for reducing inflammation and risk for CVD. 
The participants in this study did not have exceptionally high iron levels. 
 
Glucose levels increased during HIIT, and decreased during the control period. These 
results were not expected, since glucose levels normally decrease during exercise 
(Ivy, 1997). Exercise improves the insulin action and as a consequence of this, the 
glucose concentrations in blood decreases (Ivy, 1997). One explanation might be that 
some of the participants changed their diet or eating habits. Shift to a higher 
carbohydrate diet, after prolonged adaptation to fat diet, during an exercise period has 
been shown to cause increased resting muscle glycogen levels (Helge et al., 2002).  
Another explanation for the unexpected results might be that some of the participants 
did eat or drink before blood collection, which was to be taken after 12 hours fasting. 
 
 
4.3 Disease activity 
None of the parameters for disease activity, as DAS28, MHAQ and VAS-scores, 
showed significant changes, meaning that the participants neither got much worse nor 
much better after 10 weeks of HIIT. However, there were trends reporting that they felt 
better after the exercise period. Both the MHAQ questionnaire and the self reported 
global health VAS-score showed promising improvements for the disease activity. The 
VAS-score for total body pain showed a positive trend, with decreased pain, after the 
HIIT period, compared to the control period. The questionnaire SF-36, outlined in the 
radar-plot (Figure 3.3), also showed an improvement for bodily pain. Results indicate 
that HIIT improves comfort and none of the participants reported any worsening of the 
disease. The SF-36 also indicated better emotional state after the exercise period. It 
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seemed that better fitness gave better life quality. The fatigue VAS-score indicated 
decreased fatigue during the control period. This finding was unexpected. There was 
no difference between pre and post values in the HIIT period, meaning that the hard 
physical exercise did not influence the feeling of fatigue in the participants. One 
possible explanation for the observed decrease in the control group might be that half 
of the subjects had the control period post-test in June, the brightest period of the 
year, making them feel less tired. 
 
 
4.4 Molecular analysis 
4.4.1 IL-6 
In the present study IL-6 mRNA levels increased after HIIT. It has previously been 
shown that IL-6 has both pro- and anti-inflammatory activity (Petersen and Pedersen, 
2005). IL-6 is a multifunctional cytokine. It regulates humoral and cellular responses 
and plays a central role in inflammation and tissue injury. Unlike other pro-
inflammatory cytokines, IL-6 appears to be the primary inducer of acute-phase 
proteins, many of which have anti-inflammatory properties, as well as inhibiting TNF-α 
and IL-1 (Pedersen et al., 2001). During recent years, it has been demonstrated that 
IL-6 is produced locally in contracting skeletal muscles and that the net release from 
the muscle can account for the exercise-induced increase in arterial IL-6 
concentration. Physiological concentrations of IL-6 stimulate the appearance in the 
circulation of the anti-inflammatory cytokines IL-1ra and IL-10. This indicates that IL-6 
may represent an important link between contracting skeletal muscles and exercise-
related metabolic changes (Pedersen and Febbraio, 2008). In our study, blood 
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samples were taken within 48-96 hours after the last exercise. Most research on 
exercise and cytokines released from muscle, myokines, show an acute elevated level 
of IL-6 and IL-6 mRNA, not elaborating on the long-term duration of the phenomenon. 
In our case the IL-6 mRNA level was increased several days after the last exercise 
session, compared to pre-exercise levels. Chronic elevated levels of IL-6 could exert 
pro-inflammatory effects and have detrimental effects on metabolism (Pedersen and 
Fischer, 2007). The IL-6 mRNA in this study was isolated from white blood cells. 
Maximal exercise, with large muscle groups involved, provokes higher immune 
responses during repetitive bouts (Nielsen et al., 1996). IL-6 is produced in larger 
amounts than other cytokine in relation to exercise, and also plasma levels of 
cytokines increase in response to exercise. The cytokine response has been linked to 
muscle damage in earlier studies (Bruunsgaard et al., 1997), but recent studies have 
shown IL-6 to be produced without muscle damage (Pedersen, 2000). Given that IL-6 
is produced locally in skeletal muscle in response to exercise, and IL-6 is known to 
have growth factor abilities, it is likely that IL-6 plays a beneficial role and may be 
involved in mediating exercise-related metabolic changes (Pedersen, 2000). Since the 
immune system during recovery from repeated bouts of maximal exercise has been 
shown not to be normalized within seven days after the last exercise (Bruunsgaard et 
al., 1997), it is likely to assume that the increased levels of IL-6 mRNA in this study are 
mediated by muscle contractions. Other inflammations markers, such as hs-CRP and 
PTX3, did decrease after HIIT, pointing to a possible anti-inflammatory role of IL-6.  
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4.4.2  ELISA results 
COMP 
RA patients are able to increase their functional ability and physical capacity by long-
term intensive exercise (de Jong et al., 2003). It has been hypothesized that an 
increase in damage to the large joints might be a consequence of cartilage wearing, a 
potentially negative effect of high-intensity exercise. De Jong et al. found that intensive 
exercise does not increase radiographic damage of the large joints, except possibly in 
patients with considerable baseline damage of the joints. In recent years, many 
studies have aimed to identify a role for glycoproteins, as COMP, in autoimmune 
diseases and in other diseases that damage cartilaginous tissue (Morozzi et al., 2007). 
COMP is secreted first into synovial fluid and subsequently into serum, making it 
relatively simple to monitor in evaluation of the extent of cartilage damage. However, 
serum levels are significantly affected by physical exercise (Andersson et al., 2006). 
Intense physical exercise induces acute-phase inflammatory reactions, such as an 
increase in hs-CRP, CPK (creatine phosphokinase) and IL-6 levels, as a result of 
muscle contraction, muscle damage and changes in the liver (Petersen and Pedersen, 
2005). Cartilage damage and/or metabolic changes also increase during physical 
exercise, making COMP levels increase (Kim et al., 2009). Recovery to pre-exercise 
level might take several days. Kim et al. found that increased levels of COMP after an 
ultra-marathon remained high for 3 days after the race, not returning to pre-race level 
before day 6 of recovery. Another study found that increased COMP levels after 
intensive exercise could not predict longitudinal progression of damage of the large 
joints in RA patients (de Jong et al., 2008). In the present study the COMP levels 
increased in the HIIT period compared to the control. Whether this increase is a result 
of acute or permanent cartilage destruction induced by high intensity exercise is not 
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clear. Blood was collected 48-96 hours after the last exercise session, making it 
difficult to say how long of a recovery period was necessary to get levels back to 
baseline. However, since other studies have shown that COMP levels are elevated 
some days after exercise, and exercise induced high levels do not predict longitudinal 
damage, it is likely to believe that this also is the case in this study. 
 
PTX3 
The difference in PTX3 levels in this study was not statistically different, but 
manifested a decreasing trend when HIIT was compared to control. Like hs-CRP, 
PTX3 plays a role in inflammatory circuits of RA, and is a marker of atherosclerosis 
and CVD (Luchetti et al., 2000, Norata et al., 2010). Regular exercise is known to 
induce anti-inflammatory effects and protect against the risk of CVD (Petersen and 
Pedersen, 2005). For the present study, decrease, although not statistically significant 
in PTX3, could signify lower inflammation and hence lower CVD-risk. 
 
 
4.5  Limitations 
The number of participants included in this study was low. The reason for this was that 
this was considered a pilot study because high intensity physical training has not 
previously been tested in arthritis patients. Several trends were evident and inclusion 
of more patients would have enhanced the statistical power and could have produced 
statistical significance.  
 
The TNF-α ELISA kit was not highly sensitive. Well treated or healthy persons have 
values below detection limits for the kit used. Most of the participants were treated for 
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their disease, and 7 were treated with TNF-α inhibitors. Only two of the participants 
had levels high enough for detection, so a high sensitive kit had been more 
appropriate in this case. 
 
Further, the patients suffered from RA or adult JIA, which are diseases with very 
unstable disease activity. Persons suffering from these diseases may consider 
themselves healthy one day, while the next day they may experience joint pain and 
general illness. It is therefore difficult to have these conditions stabilized and subjects 
have to resort to use anti-inflammatory drugs on demand. This should be taken into 
account when reading the results, since some of the results have very high ranges and 
high standard deviations. 
 
Blood analyses were taken 4 times, pre and post HIIT, and pre and post control. The 
result reflects the status of the patient at that exact moment when the sample was 
taken, and it only gives a story of one temporal moment while offering no information 
about the underlying molecular mechanisms of the disease.  
 
At last, the cross-over-design may have resulted in the patients first included into HIIT 
to have extended benefit from the training that also translated into their control period.  
As a result they could have had better results than the patients first included as 
controls. We have tried to reduce this effect by using a wash out period of two months. 
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5.  Conclusion and practical applications 
Females with RA and JIA, with stabile disease, tolerate high intensity interval training. 
The results showed tendency towards less pain, better global health, better function, 
and decreased inflammation. Even though not all of the results were statically 
significant in response to exercise period, they showed that high intensity exercise was 
well tolerated by these patient groups. Inflammation markers were decreased during 
exercise, and inflammation and CVD risk factors are tightly connected. Other factors 
associated with decreased cardiovascular risk, such as increased VO2max, decreased 
BMI, decreased waist circumference, and decreased total and visceral fat, showed 
that women with RA and JIA decreased the risk of cardiovascular diseases with HIIT. 
Questionnaires used in this study showed that the HIIT improved the score for 
performing activities of daily living, achieved better score for general health, reduced 
pain, and gave fewer stressors with work or daily activities caused by emotional 
problems. In general, HIIT improved the quality of life in persons with RA and JIA.  
In conclusion, ten weeks of high intensity interval training was well tolerated by 
females with RA and JIA, and improved the disease activity, quality of life, and 
traditionally risk factors for cardiovascular diseases. This study suggests that high 
intensity interval training can be safely recommended for persons with RA and JIA. 
 
 
Future directions 
The present study examined the effect of HIIT on premenopausal females with RA or 
JIA over a period of 10 weeks. Several questions raises for future studies, as the effect 
of the HIIT intervention on similar groups with longer duration, effect on other 
rheumatic diseases, effect on both genders, and effect on other elderly or younger 
patients. Further investigations are needed for HIIT and rheumatic diseases. IL-6 
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levels also need more investigation, since it is still unclear whether increased levels 
are a good or a bad thing for joint inflammation and rheumatic diseases.  
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